Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

SABCS 2010: Obesity Ups Risk of Recurrence for Some Women With HER2-Negative Breast Cancer

March 4th 2011

Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

March 4th 2011

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the Literature

March 3rd 2011

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.

10 Tips for Breast Cancer Patients During Treatment

March 3rd 2011

10 helpful tips to remember during treatment for patients struggling with breast cancer

False-Positive Mammograms Lead to Anxiety and Quality-of-Life Issues

March 2nd 2011

A false-positive result on a mammogram may trigger anxiety and decrease quality of life, and the effects may remain apparent a year later, new data suggest.

Breastfeeding May Benefit Childhood Cancer Survivors

March 2nd 2011

For women who have survived childhood cancer, breastfeeding may help counter some of the long-term complications that occur as a result of their prior cancer treatments, researchers say.

SABCS Coverage: Adding Everolimus to Tamoxifen Improves Outcomes in Metastatic Breast Cancer

March 2nd 2011

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer

SABCS Coverage: Denosumab Bests Zoledronic Acid at Preventing Bone Complications in Patients With Breast Cancer

March 2nd 2011

Investigators for Study 136 say that an additional 4 months of follow-up data have confirmed earlier findings that denosumab (Xgeva) is superior to zoledronic acid (Zometa) at preventing skeletal-related events

SABCS Coverage: Fulvestrant Prolongs Time to Progression in Breast Cancer

March 2nd 2011

Women with untreated advanced breast cancer had a trend toward greater clinical benefit with fulvestrant (Faslodex) versus anastrozole (Arimidex) as first-line hormonal therapy

SABCS Coverage: MA.27 Study Finds Exemestane and Anastrozole Comparable

March 2nd 2011

Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer

Oncology Community Facing Severe Drug Shortages

December 19th 2010

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.

Flash Findings

August 17th 2010

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer

GSK%u2019s Tykerbï¿½ Approved for Advanced Breast Cancer

August 12th 2010

With FDA approval for their advanced breast cancer drug Tykerbï¿½, GlaxoSmithKline is poised to reposition itself as a major player in the oncology business.

HRT Linked with Breast and Ovarian Cancers

July 12th 2010

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

News Reports from the 2007 Breast Cancer Symposium

June 30th 2010

The first annual 2007 Cancer Symposium, held September 7-8 in San Francisco, provided an opportunity for members of the oncology community to discuss major developments in breast cancer treatment and research.

Updates from the Breast Cancer Symposium

June 30th 2010

In 2007, more than 240,000 persons will receive a diagnosis of breast cancer and nearly 41,000 will die from the disease. Although survival rates have shown significant improvement over the past several decades, breast cancer continues to be the second most common cause of cancer death in women.

Updates from Oncology Meetings

June 30th 2010

Oncology & Biotech News provides updates from major oncology meetings because symposia remain an important means for disseminating new data. This issue, we highlight two important meetings: 2007 Breast Cancer Symposium (in San Francisco) and the World Conference on Lung Cancer (in Korea).

Examining MammaPrintÂ®: An Interview with Richard Bender, MD

May 6th 2010

In the United States, more than 200,000 women receive a breast cancer diagnosis annually. Early detection offers patients the best chance for a cure, but may also lead to treatment dilemmas in some patients.

Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes

April 4th 2010

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.

Getting Cancer Patients to Eat for Life

June 5th 2009

Studies have also shown that diet and exercise help prevent breast cancer, yet obesity rates in women continue to rise. New information suggests women with early stage breast cancer can prolong their lives by following a prudent diet.